| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5419 | Vitexin 4"-o-glucoside | Natural inhibitor of ST2 (IL1RL1) |
|
| DCC5420 | Viviren | Coelenterazine analog for bioluminescence imaging (BLI) |
|
| DCC5421 | Vmy-1-101 | Fluorescent cyclin-dependent kinase inhibitor, blocking the proliferation of human breast cancer cells |
|
| DCC5422 | vmy-2-95 | Novel and selective desensitizer of |
|
| DCC5423 | Setmelanotide Tfa Salt Featured | Novel highly-selective melanocortin-4 receptor (MC4R) agonist, increasing resting energy expenditure in obese individuals |
.png)
|
| DCC5424 | Voa Analog 19 | Novel potent VEGFR2 modulator, exhibiting increased antiangiogenic potency than voacangine against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects, resulting in significant tumor cell death in a mouse xenograft model |
|
| DCC5425 | Voclosporin | Novel calcineurin inhibitor and immunosuppressive agent |
|
| DCC5426 | Vonoprazan Fumurate | Novel potassium-competitive acid blocker |
|
| DCC5427 | Vpc-00628 | Novel potent and highly selective type-II inhibitor of p38α/β, targeting an inactive state of the kinases induced by a unique folded P-loop conformation |
|
| DCC5428 | Vpc-13163 | Potent Antiandrogen, Targeting the BF3 Site of the Androgen Receptor and Inhibiting Enzalutamide-Resistant Prostate Cancer |
|
| DCC5429 | Vpc-16606 | Novel potent and selective inhibitor of ERα-dependent cell growth and gene expression, preventing the interaction between ERα-LBD and SRC-3 fusion proteins in a dose-dependent manner |
|
| DCC5430 | Vpc24191 | S1P1/S1P3 receptor agonist |
|
| DCC5431 | Vpc-3033 | Novel Androgen Receptor Antagonist, inhibiting the LNCaP cell line as well as cell lines with wild-type androgen receptor |
|
| DCC5432 | Vpc44116 | Competitive S1P1/3 antagonist, increasing capillary permeability as measured by Evans blue dye leakage in mouse lung tissue |
|
| DCC5433 | Vrt-325 | Corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant |
|
| DCC5434 | Vrv-pl-viiia Inhibitor 5m | Inhibitor of the catalytic activity of VRV-PL-VIIIa, strongly inhibiting the hemolysis of red blood cells and VRV-PL-VIIIa-induced myotoxicity and lung hemorrhage in mice |
|
| DCC5435 | Vrx-480773 | Novel Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) |
|
| DCC5436 | Vsw1198 | Novel inhibitor of geranylgeranyl diphosphate synthase (GGDPS) |
|
| DCC5437 | Vswrapta | Novel Promoter of Neuronal Branching Via Transcellular Activation of the Focal Adhesion Kinase (FAK) and the ERK1/2 Signaling Pathway In Vitro |
|
| DCC5438 | Vt-me6 | Sphingosine kinase (SphK) inhibitor, having modest SphK2-selectivity |
|
| DCC5439 | Vtx-2337 Analog-1 | Novel selective agonist of TLR8 |
|
| DCC5440 | Vu0034403 | Novel non-MPEP site metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs) |
|
| DCC5441 | Vu0160573 | Selective modulator of G protein-coupled inward rectifier K (GIRK) |
|
| DCC5442 | Vu0184670 | Allosteric modulator of the M1 muscarinic receptor |
|
| DCC5443 | vu0360173 | Novel Positive Allosteric Modulator (PAM) of the Metabotropic Glutamate Receptor 5 (mGlu5) |
|
| DCC5444 | Vu0361747 | Novel Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5, Revealing Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity |
|
| DCC5445 | Vu0364289 | Potent and specific PAM for the rat mGluR5 receptor |
|
| DCC5446 | Vu0366058 | Potent noncompetitive antagonist of Metabotropic_glutamate_receptor_5>metabotropic glutamate receptor 5 (mGlu5) |
|
| DCC5447 | Vu0366248 Featured | VU0366248 is a mGlu5 negative allosteric modulator. |
|
| DCC5448 | vu0403602 | Novel Positive Allosteric Modulator (PAM) of the Metabotropic Glutamate Receptor 5 (mGlu5) |
|
